0001209191-24-003269.txt : 20240213
0001209191-24-003269.hdr.sgml : 20240213
20240213201730
ACCESSION NUMBER: 0001209191-24-003269
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240209
FILED AS OF DATE: 20240213
DATE AS OF CHANGE: 20240213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Seely Lynn
CENTRAL INDEX KEY: 0001327111
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40502
FILM NUMBER: 24631359
MAIL ADDRESS:
STREET 1: 501 2ND STREET
STREET 2: SUITE 211
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyell Immunopharma, Inc.
CENTRAL INDEX KEY: 0001806952
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 833006753
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650 695-0677
MAIL ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-02-09
0
0001806952
Lyell Immunopharma, Inc.
LYEL
0001327111
Seely Lynn
C/O LYELL IMMUNOPHARMA, INC.
201 HASKINS WAY
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
0
Common Stock
2024-02-09
4
A
0
200000
0.00
A
200000
D
The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
/s/ Charles Newton, as Attorney-in-Fact
2024-02-13